A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors-Reference-Cited by-同舟云学术

A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors

Published:2020-06-19 Issue:5 Volume:31 Page:685-690
ISSN:0953-7104
Container-title:Platelets
language:en
Short-container-title:Platelets

Author:

Nicolson Phillip LR.¹^ORCID,Welsh John D.²,Chauhan Abhishek³,Thomas Mark R.¹,Kahn Mark L.²,Watson Steve P.¹⁴

Affiliation:

1. Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

2. Department of Medicine and Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA

3. Centre for Liver Research, Institute of Immunology and Inflammation, and National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK

4. Centre of Membrane Proteins and Receptors, The Universities of Birmingham and Nottingham, The Midlands, UK

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/09537104.2020.1775189

Reference54 articles.

1. WHO situation report 117.2020. WHO. [internet]. [accessed May 17 2020]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

2. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

3. Clinical Characteristics of Coronavirus Disease 2019 in China

4. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

5. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists;Communications Biology;2023-04-07

2. Blood Coagulation and Beyond: Position Paper from the Fourth Maastricht Consensus Conference on Thrombosis;Thrombosis and Haemostasis;2023-03-13

3. The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity;Journal of Thrombosis and Haemostasis;2022-12

4. Platelets and tyrosine kinase inhibitors: clinical features, mechanisms of action, and effects on physiology;American Journal of Physiology-Cell Physiology;2022-10-01

5. Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs;International Journal of Molecular Sciences;2022-06-23